Probi AB (publ) PROB.ST Stock
Probi AB (publ) Price Chart
Probi AB (publ) PROB.ST Financial and Trading Overview
| Probi AB (publ) stock price | 216 SEK |
| Previous Close | 185 SEK |
| Open | 181 SEK |
| Bid | 181.5 SEK x 0 |
| Ask | 185 SEK x 0 |
| Day's Range | 180 - 184 SEK |
| 52 Week Range | 165 - 320 SEK |
| Volume | 44 SEK |
| Avg. Volume | 954 SEK |
| Market Cap | 2.06B SEK |
| Beta (5Y Monthly) | 0.549042 |
| PE Ratio (TTM) | 44.91315 |
| EPS (TTM) | 1.49 SEK |
| Forward Dividend & Yield | 1.3 (0.69%) |
| Ex-Dividend Date | May 5, 2023 |
| 1y Target Est | N/A |
PROB.ST Valuation Measures
| Enterprise Value | 1.86B SEK |
| Trailing P/E | 44.91315 |
| Forward P/E | 25.820255 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 3.2457943 |
| Price/Book (mrq) | 1.4466691 |
| Enterprise Value/Revenue | 2.921 |
| Enterprise Value/EBITDA | 15.031 |
Trading Information
Probi AB (publ) Stock Price History
| Beta (5Y Monthly) | 0.549042 |
| 52-Week Change | -24.58% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 320 SEK |
| 52 Week Low | 165 SEK |
| 50-Day Moving Average | 183.24 SEK |
| 200-Day Moving Average | 199.56 SEK |
PROB.ST Share Statistics
| Avg. Volume (3 month) | 954 SEK |
| Avg. Daily Volume (10-Days) | 1.09K SEK |
| Shares Outstanding | 11.39M |
| Float | 3.05M |
| Short Ratio | N/A |
| % Held by Insiders | 70.37% |
| % Held by Institutions | 19.79% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 1.3 |
| Trailing Annual Dividend Yield | 0.70% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0.32259998 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 7.21% |
| Operating Margin (ttm) | 8.76% |
| Gross Margin | 41.32% |
| EBITDA Margin | 19.43% |
Management Effectiveness
| Return on Assets (ttm) | 2.28% |
| Return on Equity (ttm) | 3.36% |
Income Statement
| Revenue (ttm) | 635.39M SEK |
| Revenue Per Share (ttm) | 55.76 SEK |
| Quarterly Revenue Growth (yoy) | 11.09% |
| Gross Profit (ttm) | 255.45M SEK |
| EBITDA | 123.49M SEK |
| Net Income Avi to Common (ttm) | 45.88M SEK |
| Diluted EPS (ttm) | 4.03 |
| Quarterly Earnings Growth (yoy) | 37.50% |
Balance Sheet
| Total Cash (mrq) | 317.96M SEK |
| Total Cash Per Share (mrq) | 27.91 SEK |
| Total Debt (mrq) | 66.18M SEK |
| Total Debt/Equity (mrq) | 4.64 SEK |
| Current Ratio (mrq) | 5.857 |
| Book Value Per Share (mrq) | 125.115 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 130.97M SEK |
| Levered Free Cash Flow (ttm) | 40.69M SEK |
Profile of Probi AB (publ)
| Country | Sweden |
| State | N/A |
| City | Lund |
| Address | Ideongatan 1A |
| ZIP | 223 70 |
| Phone | 46 4 62 86 89 20 |
| Website | https://www.probi.com |
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 172 |
Probi AB (publ) researches, manufactures, and sells probiotics for dietary supplements and food companies in North America, South America, Europe, the Middle East, Africa, Asia, and Pacific. The company conducts research primarily in the fields of gastrointestinal health, digestive health, immune health, bone health, and iron absorption, as well as children's, women's, and senior health. It provides dietary supplement, and food and beverage products in the form of capsules, tablets and spheres, chewable tablets, powder, fruit drinks, shots, carbonated beverages, and recovery drinks. The company sells its products approximately in 40 countries worldwide. It has a collaboration with Örebro University for research into exploration needle free vaccines; University of Gothenburg to investigate the effects of probiotic strain LP299V on iron absorption; Wageningen University & Research to understand the molecular interactions occurring between microbes and its hosts; University of Umeå to investigate the effects of the strain LP299V on iron status in female athletes; and University of Aberdeen to characterize bacterial isolates with next generation probiotics. The company was incorporated in 1991 and is headquartered in Lund, Sweden. Probi AB (publ) is a subsidiary of Symrise AG.
Q&A For Probi AB (publ) Stock
What is a current PROB.ST stock price?
Probi AB (publ) PROB.ST stock price today per share is 216 SEK.
How to purchase Probi AB (publ) stock?
You can buy PROB.ST shares on the Stockholm exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Probi AB (publ)?
The stock symbol or ticker of Probi AB (publ) is PROB.ST.
Which industry does the Probi AB (publ) company belong to?
The Probi AB (publ) industry is Drug Manufacturers-Specialty & Generic.
How many shares does Probi AB (publ) have in circulation?
The max supply of Probi AB (publ) shares is 11.39M.
What is Probi AB (publ) Price to Earnings Ratio (PE Ratio)?
Probi AB (publ) PE Ratio is 144.96645000 now.
What was Probi AB (publ) earnings per share over the trailing 12 months (TTM)?
Probi AB (publ) EPS is 1.49 SEK over the trailing 12 months.
Which sector does the Probi AB (publ) company belong to?
The Probi AB (publ) sector is Healthcare.
Probi AB (publ) PROB.ST included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| OMX_Nordic_Mid_Cap_DKK_GI OMXNMCDKKGI | 439.38 DKK 64.42 USD |
-0.4
|
— — | — — | — — | — - | — — |
| OMX Stockholm Health Care PI SX4000PI | 2712.52 SEK 264.78 USD |
<0.01
|
— — | — — | — — | — - | — — |
| OMX Stockholm Health Care GI SX20GI | 4204.43 SEK 410.4 USD |
-0.07
|
— — | — — | — — | — - | — — |
| OMX Stockholm Pharmaceuticals a SX201030GI | 6954.45 SEK 678.84 USD |
+0.49
|
— — | — — | — — | — - | — — |
| OMX_Stockholm_Mid_Cap_PI OMXSMCPI | 1516.78 SEK 148.06 USD |
-0.02
|
— — | — — | — — | — - | — — |
| OMX Stockholm_GI OMXSGI | 466.5 SEK 45.54 USD |
+0.02
|
— — | — — | — — | — - | — — |
| OMX_Nordic_Mid_Cap_SEK_GI OMXNMCSEKGI | 548.69 SEK 53.56 USD |
+0.07
|
— — | — — | — — | — - | — — |
| OMX_Nordic_Mid_Cap_EUR_GI OMXNMCEURGI | 439.19 EUR 480.1 USD |
-0.42
|
— — | — — | — — | — - | — — |
| OMX Affarsvarldens Generalindex OMXAFGX | 923.83 SEK 90.18 USD |
-0.03
|
— — | — — | — — | — - | — — |
| OMX Stockholm Health Care PI SX20PI | 3276.93 SEK 319.87 USD |
-0.07
|
— — | — — | — — | — - | — — |
| OMX Stockholm Pharmaceuticals a SX201030PI | 5132.25 SEK 500.97 USD |
+0.49
|
— — | — — | — — | — - | — — |
| OMX Stockholm_PI OMXSPI | 947.32 SEK 92.47 USD |
-0.04
|
— — | — — | — — | — - | — — |
| OMX_Stockholm_Mid_Cap_GI OMXSMCGI | 796.9 SEK 77.79 USD |
-0.02
|
— — | — — | — — | — - | — — |
| OMX Stockholm All-Share Cap_GI OMXSCAPGI | 456.92 SEK 44.6 USD |
+0.02
|
— — | — — | — — | — - | — — |
| OMX_Nordic_Mid_Cap_ISK_GI OMXNMCISKGI | 622.38 ISK 4.58 USD |
-0.43
|
— — | — — | — — | — - | — — |
- {{ link.label }} {{link}}